Citations

Clear

250 citation(s) found for "Faubion, W A".

Validation of the Perimenopause Symptom Scale (Peri-SS) for digital self-assessment: psychometric evaluation among US women aged 35 to 59 years
Xu, Yihan , Faubion, Stephanie

Mayo Clinic

Menopause | November 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/gme.0000000000002948 | PMID 43012501 Get It

Objective: Perimenopause is an under-recognized transition poorly measured by existing tools, which often overlook symptoms characteristic of this phase. To address this, we developed and validated the Perimenopause Symptom Scale (Peri-SS): a concise, phase-specific, psychometrically robust instrument for digital self-assessment and research use among US women aged 35-59 who self-reported being in perimenopause. Methods: We conducted a longitudinal validation study with 1,255 US women aged 35-59 (633 self-identified as perimenopausal) recruited via Prolific. Participants completed the Peri-SS, Menopause Rating Scale (MRS), and EuroQol 5-Dimension, 5-Level (EQ-5D-5L) questionnaire at baseline and 7-14 days later. Following COSMIN guidelines, we assessed structural validity, internal consistency, test-retest reliability, criterion and construct validity, and responsiveness to change. Results: The Peri-SS demonstrated strong psychometric performance. Confirmatory factor analysis confirmed a four-domain structure (vasomotor, psychological, sexual, physical), with excellent model fit (CFI=0.932, RMSEA=0.069). Internal consistency was excellent (α=0.90 overall; domain range 0.73-0.86), and test-retest reliability was high (ICC=0.82). Criterion validity was strong, with Peri-SS scores highly correlated with Menopause Rating Scale ( r =0.88). Construct validity was supported through moderate correlations with EQ-5D-5L utilities (ρ=−0.50) and effective discrimination between groups by age, reproductive stage, and hormone therapy use. The scale was also responsive to symptom changes over time (η²=0.277). Conclusions: The Peri-SS is a reliable, valid, responsive tool for assessing perimenopausal symptom burden. Its concise format and strong psychometric performance make it well-suited for research, clinical care, and digital health applications.
Evolving Treatment Patterns and Clinical Outcomes in Children with Newly Diagnosed Crohn's Disease and Ulcerative Colitis in the United States, 2007–2023
Gonzalez, Michelle , Qi, Yuchen , Xu, Ronghui , Jairath, Vipul, Goodwin, Shane W. , Olén, Ola , Faubion, William A. , Kappelman, Michael D. , Singh, Siddharth

Mayo Clinic

American Journal of Gastroenterology | October 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004219 | PMID 42841617 Get It

Background & Aims: We examined treatment patterns and clinical outcomes in a contemporary cohort of children with newly diagnosed inflammatory bowel disease (IBD) in a large, commercially insured U.S. population. Methods: Using the OptumLabs® Data Warehouse, we created an inception cohort of physician-diagnosed IBD in children aged 6–17 years between 2007–23. We examined cumulative incidence of hospitalization, surgery, safety events, and medication use in patients with Crohn's disease (CD) and ulcerative colitis (UC), overall and stratified by diagnostic era, race and ethnicity, sex, and age at diagnosis. Results: Among 787 children with newly diagnosed CD (age at diagnosis, 13.4±2.9y; 57% male; 82% White, 5% Black, 7% Hispanic) followed over mean 4.6±3.0y, 5-year risk of IBD-related hospitalization and major surgery was 30% and 10%, respectively. In children diagnosed in 2019–23, 1-year cumulative use of corticosteroids and advanced therapy was 46% and 75%, respectively; advanced therapy use increased significantly over time (aHR, 3.43 [95% CI, 2.71–4.32] for 2019–23 vs. 2007–12), while corticosteroid use declined (0.67 [0.53–0.84]). Risk of IBD-related hospitalization was lower in children diagnosed between 2019–23 (0.65 [0.43–0.97]) compared with those diagnosed between 2007-12; surgical risk did not decline significantly, with confidence intervals compatible with a clinically meaningful reduction. Among 399 children with newly diagnosed UC (age at diagnosis, 14.0±3.0y; 53% male; 78% White, 5% Black, 7% Hispanic) followed over 4.5±3.0y, 5-year risk of IBD-related hospitalization and colectomy was 36% and 8%, respectively. Advanced therapy use increased significantly over time (4.46 [2.85–6.98] for 2019–23 vs. 2007–12), with no significant change in hospitalization or surgical risk across eras. No consistent racial and ethnic, age, or sex differences in advanced therapy use or clinical outcomes were identified in either CD or UC. Conclusions: In a contemporary cohort of commercially insured children with newly diagnosed IBD, early advanced therapy use has increased markedly over time. Surgical risk did not decline significantly in either disease; however, the study was not powered to exclude a clinically meaningful reduction, and these findings are hypothesis-generating rather than conclusive.
Metabolic reprogramming of pathogenic CD4 + T helper cells attenuates inflammatory bowel disease in mice
Mishra, Shravan K , Abdelrahman, Leena M , Kim Lee, Hyun Se , Valenzuela-Pérez, Lucía , Manna, Dina Faeq , Abram, Tanner J , Ali, Lama Mohamed , Davidson, Heidi M , Hassan, Omar M , Faubion, William A. , Hirsova, Petra , Bamidele, Adebowale O

Mayo Clinic

Science Signaling | October 6, 2026 | Volume: 19 | Issue: 958 | Pages: No page available

10.1126/scisignal.aeb2392 | PMID 42837442 Get It

CD4 + effector T helper 1 (T H 1) cells drive inflammatory bowel disease (IBD). Here, we investigated how integrated signaling, metabolic, and epigenetic programs sustain their pathogenic persistence. We found that enforcing mitochondrial pyruvate metabolism with methyl pyruvate (MePyr) suppressed T H 1 cell effector function and induced the acquisition of a regulatory-like phenotype. MePyr suppressed the activity of glycogen synthase kinase 3β (GSK3β), promoting a metabolic shift from glycolysis toward oxidative phosphorylation (OXPHOS) and limiting the accumulation of intracellular acetyl-CoA. This metabolic reprogramming decreased histone H3 acetylation at genes encoding inflammatory cytokines, thereby decreasing T H 1 cell–associated gene expression. Restoration of inflammatory cytokine production by acetate supplementation or histone deacetylase inhibition established acetyl-CoA–dependent histone acetylation as a mechanistic link between metabolic flux and effector function. Conversely, the cytokine interleukin-21 enhanced T H 1 cell effector activity by promoting a GSK3β-dependent shift from OXPHOS to glycolysis. Single-cell transcriptomic analysis of Crohn’s disease tissue revealed enrichment of glycolytic gene programs in nonregulatory CD4 + T cells. Consistent with these findings, pharmacologic inhibition of GSK3β attenuated disease severity in a T cell–transfer mouse model of colitis. Together, these findings identify a GSK3β-dependent metabolic-epigenetic axis that sustains T H 1 cell pathogenicity and highlight GSK3β as a potential therapeutic target for IBD.
The New ACP Clinical Guideline for the Pharmacologic Treatment of Menopausal Vasomotor Symptoms: Where Do We Go From Here?
Castaneda, Regina , Faubion, Stephanie S

Mayo Clinic

Annals of Internal Medicine | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7326/annals-26-03184 | PMID 42832806 Get It

Functional Hypothalamic Amenorrhea Phenotype and Cardiovascular Disease Risk
Stuart, Jennifer , Karam, Jana , Che, Xiaoyu , Manson, JoAnn E. , Miller, Karen K. , Rexrode, Kathy, Faubion, Stephanie S. , Berga, Sarah L. , Merz, C. Noel Bairey , Rich‐Edwards, Janet W.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1210/clinem/dgag405 | PMID 42831273 Get It

Abstract Context Menstrual irregularities have been associated with cardiovascular disease (CVD) risk, but underlying etiologies may confer distinct risk profiles. Functional hypothalamic amenorrhea (FHA) has not been evaluated as a separate risk phenotype. Objective To assess the association between FHA phenotype and incident CVD and cardiometabolic risk factors. Design Prospective cohort study with biennial follow-up from 1993 to 2019. Setting Nurses’ Health Study II cohort. Participants The sample included 52,655 premenopausal women free of CVD in 1993. FHA phenotype was defined as irregular or absent cycles without PCOS traits combined with low body mass index and/or high physical activity. Intervention None Main Outcome Measures Incident CVD (coronary heart disease [CHD; myocardial infarction or coronary revascularization] and stroke) and incident elevated cholesterol, hypertension, and type 2 diabetes (T2DM). Results During up to 26 years of follow-up, 1,007 CVD events occurred. Among women who developed CVD, the median time to the first CVD event was 17.0 years (IQR, 11.3-21.0). FHA phenotype in mid-adulthood was associated with a 62% higher risk of CVD (95% confidence interval [CI]: 1.01–2.59), driven by an almost two-fold higher risk of CHD (hazard ratio [HR] = 1.91; 95% CI: 1.11–3.27), compared with women with regular cycles. FHA was also associated with T2DM (HR = 1.86; 95% CI: 1.41–2.47), but not hypertension or elevated cholesterol. Non-FHA menstrual irregularity was associated with elevated cholesterol, hypertension, and T2DM, but not CVD. FHA in early adulthood was not associated with outcomes. Conclusions FHA phenotype in mid-adulthood was associated with increased CHD risk independent of traditional risk factors. Menstrual history may serve as an early marker of cardiometabolic risk.
Extended normothermic machine perfusion preserves viability and tissue integrity of ex vivo human intestine segments
Urbina, Pamela A. Manco, Choi, Sae Rome, Cheung, Dillon C., Egbert, Lena K. , Garcia-Neuer, Marlene I., Yu, Stephanie, Rehman, Nisha S., Hanks, Danielle G., Le, Tuan‐Anh , Alabay, Husnu H., McHugh, Kelsey , Hamdan, Feda H., Naik, Nimesh, Faubion, William A. , Brady, Justin T. , Ceylan, Hakan , Bose, Suman , Urbina, Pamela Allison Manco , Garcia-Neuer, Marlene , Rehman, Nabeela, Alabay, Husnu Halid , Hamdan, Feda H. , Naik, Nimesh D.

Mayo Clinic

No container title available | September 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.17.752436 Get It

ABSTRACT Human intestinal diseases, including inflammatory bowel disease (IBD), are difficult to model because existing animal and in vitro systems do not capture the intestine’s integrated vascular, immune, and metabolic complexity. Here, we establish a custom normothermic machine perfusion platform that maintains surgically resected human intestinal tissue for up to 72 hours under near-physiological conditions. Discarded specimens from patients with nonmalignant intestinal diseases, including IBD and diverticulitis, were continuously perfused at 37°C with real-time hemodynamic and metabolic monitoring. Perfusion preserved tissue viability, mucosal architecture, epithelial integrity, oxygen consumption, metabolic activity, and vascular patency. Daily perfusate sampling enabled longitudinal profiling and experimental modulation of inflammatory mediators, revealing patient-specific immune states. This long-duration platform bridges reductionist in vitro models and clinical disease, enabling mechanistic studies of intestinal inflammation and future testing of personalized therapies in intact patient-derived tissue.
A mobile app compared with an educational pamphlet on menopause hormone therapy initiation: a randomized pilot study
Kling, Juliana M., French, Courtney A., Kapoor, Ekta, Hedges, Mary S., Deng, Yihong, Chaudhry, Rajeev, Smith, Jamie L., Cole, Kristin C., Shufelt, Chrisandra , Karens, Arjan, Faubion, Stephanie S., Smith, Jamie L , Kling, Juliana M. , Kapoor, Ekta , Hedges, Mary S. , Paul, Margaret M. , Chaudhry, Rajeev , Castaneda, Regina , Faubion, Stephanie S.

Mayo Clinic

Frontiers in Reproductive Health | September 16, 2026 | Volume: 8 | Issue: No issue available | Pages: No page available

10.3389/frph.2026.1952673 | PMID 42819486 Get It

Background Menopause-related symptoms are common but undertreated. Digital tools that support symptom assessment and patient education may improve engagement. Objective To assess whether a previsit digital menopause symptom assessment and education tool increased treatment initiation and patient engagement compared to an educational pamphlet. Design Women aged 45–55 years with upcoming primary care appointments were invited to participate. Those with a total Menopause Rating Scale (MRS) score ≥5 indicating bothersome menopause symptoms were included. Participants were randomized to a digital menopause symptom assessment tool or a digital educational pamphlet and completed a post-visit survey (NCT06919887). Participants Of the 14,726 women invited to participate between May 12, 2025, and December 5, 2025, there were 653 (4.4%) enrolled that met eligibility criteria. Interventions Randomized to an mHealth app called emmii or a standard digital menopause educational pamphlet. Main measures Menopause treatment initiation within 30 days of the clinical visit was assessed by electronic health data. Baseline and post-visit surveys were collected assessing patient experience, engagement, and perceived usefulness. Rates of menopause hormone therapy (HT) prescribing were compared with a reference population of nonparticipants aged 45–55 who had a primary care appointment at Mayo Clinic during the same period and received no study education materials. Key results Of 653 participants enrolled and randomized, 383 completed both the baseline and post-surveys (171 intervention and 212 control). HT initiation among study participants was significantly higher than in the reference population of women (9.3% vs. 4.4%, p < 0.001). There was no difference in HT initiation between the intervention (9.1%) and control groups (9.6%) ( p = 0.83). Initiation rates were 3.8% and 4.5%, respectively ( p = 0.64) for nonhormone therapies. Conclusions Among women with bothersome menopause symptoms, those who underwent previsit symptom screening and received educational materials had higher rates of HT initiation than women who did not participate in the study. These findings suggest that structured menopause education may improve recognition and management of menopause symptoms in routine clinical practice.
Menopausal Hormone Therapy and Cardiovascular—Laying the Foundation for Future Trials
Castaneda, Regina, Faubion, Stephanie S., Castaneda, Regina , Faubion, Stephanie S.

Mayo Clinic

JAMA Internal Medicine | September 8, 2026 | Volume: 186 | Issue: 11 | Pages: 1332

10.1001/jamainternmed.2026.2877 | PMID 42709427 Get It

Update in Sexual Health
Faubion, Laura L. , Kling, Juliana M. , Kling, Juliana M

Mayo Clinic

Journal of Women's Health | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15409996261483619 | PMID 42634151 Get It

The goal in selecting these recent articles was to help identify literature that may change the clinical practice of women’s health for practitioners in the primary care and general gynecology setting. Articles were identified by reviewing high-impact medical and women’s health journals, national guidelines, ACP JournalWise and NEJM Journal Watch. In this Clinical Update, we selected recent publications relevant to the sexual health of women. Specifically, we reviewed guidelines and consensus statements on hypoactive sexual desire disorder (HSDD) and genitourinary syndrome of menopause (GSM), as well as studies around the role of pelvic floor muscle training for GSM and psychological and behavioral health for sexual health in midlife women.